Johnson & Johnson
NYSE:JNJ
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
142.2123
167.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Johnson & Johnson
Johnson & Johnson
Revenue
Johnson & Johnson
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$87.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$60.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
Johnson & Johnson
Revenue Breakdown
Breakdown by Geography
Johnson & Johnson
|
Total Revenue:
85.2B
USD
|
|
United States Plans:
46.4B
USD
|
|
Non-Us:
38.7B
USD
|
Breakdown by Segments
Johnson & Johnson
|
Total Revenue:
85.2B
USD
|
|
Innovative Medicine:
54.8B
USD
|
|
Medtech:
30.4B
USD
|
|
Stelara:
10.9B
USD
|
|
Darzalex:
9.7B
USD
|
|
General:
5.4B
USD
|
|
Electrophysiology:
4.7B
USD
|
|
Advanced:
4.7B
USD
|
|
Invega Sustenna/Xeplion/Trinza/Trevicta:
4.1B
USD
|
|
Contact Lenses/Other:
3.7B
USD
|
|
Imbruvica:
3.3B
USD
|
|
Tremfya:
3.1B
USD
|
|
Trauma:
3B
USD
|
|
Spine,Sports & Other:
2.9B
USD
|
|
Erleada:
2.4B
USD
|
|
Xarelto:
2.4B
USD
|
|
Simponi/Simponi Aria:
2.2B
USD
|
|
Opsumit:
2B
USD
|
|
Prezista/Prezcobix/Rezolsta/Symtuza:
1.9B
USD
|
|
Remicade:
1.8B
USD
|
|
Uptravi:
1.6B
USD
|
|
Hips:
1.6B
USD
|
|
Other Neuroscience:
1.6B
USD
|
|
Knees:
1.5B
USD
|
|
Surgical:
1.4B
USD
|
|
Abiomed:
1.3B
USD
|
|
Other:
1.3B
USD
|
|
Edurant/Rilpivirine:
1.2B
USD
|
|
Covid-19:
1.1B
USD
|
|
Zytiga/Abiraterone Acetate:
887m
USD
|
|
Other Oncology:
879m
USD
|
|
Concerta/Methylphenidate:
783m
USD
|
|
Risperdal Consta:
689m
USD
|
|
Carvykti:
500m
USD
|
|
Other Interventional Solutions:
356m
USD
|
|
Other Infectious Diseases:
297m
USD
|
|
Other Immunology:
11m
USD
|
Johnson & Johnson
Glance View
Johnson & Johnson, often referred to as J&J, is a global healthcare giant that operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. Founded in 1886, the company has built a strong reputation for its innovative products, which range from life-saving prescription medications to everyday consumer items such as Band-Aids and Tylenol. With a commitment to improving health and well-being, J&J has consistently invested in research and development, yielding a robust pipeline of drugs and technologies that address critical health challenges, including oncology, immunology, and infectious diseases. This ongoing innovation positions the company favorably in a competitive landscape, ensuring sustained revenue growth and profitability. For investors, Johnson & Johnson represents a compelling opportunity not only due to its diversified business model but also its robust financial health. The company boasts a history of steady revenue growth, strong cash flow generation, and a reliable dividend, making it a perennial favorite for income-focused investors. While it has faced some legal challenges and market pressures, J&J’s ability to adapt and respond to these issues has underscored its resilience. With a strong balance sheet and a global footprint in the ever-growing healthcare sector, Johnson & Johnson continues to demonstrate why it is often regarded as a cornerstone investment in a well-rounded portfolio.
See Also
What is Johnson & Johnson's Revenue?
Revenue
87.7B
USD
Based on the financial report for Sep 29, 2024, Johnson & Johnson's Revenue amounts to 87.7B USD.
What is Johnson & Johnson's Revenue growth rate?
Revenue CAGR 10Y
2%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Johnson & Johnson have been -1% over the past three years , 1% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
